The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
One of the issues with vaccine development is the enormous time required to produce one. The Covid-19 vaccine has shown the process can be expedited. But can the process be made even more faster?
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
RDIF has tied up with nearly a dozen contract manufacturers with idle capacity to produce some 1.5 billion doses of Sputnik V annually, more than what Serum and Bharat Biotech will jointly produce.
In the context of vaccination, effective communication should deliver clarity around who, when, where, and how much the vaccine will cost. And India's vaccine deployment can be a great case study.
The second phase of the Covid-19 vaccine, which is currently underway, requires the private sector's involvement more than ever before. And the sector is rising up to the challenge.
The Covid-19 pandemic has amplified the importance of cold-chain infrastructure, and Godrej Appliances’ medical refrigeration business is making the most of the opportunity.
With the Covid-19 vaccination drive entering phase 2 in India, it is important to emphasise the positive role the private sector can play in facilitating the vaccine's availability for the masses.
With two vaccines having received emergency use authorisation, India is prepared to meet the logistical challenge. For now, the deployment has begun with the vaccination of healthcare workers.
